ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.
Profitability
This table compares ProQR Therapeutics and Viridian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProQR Therapeutics | -223.51% | -73.83% | -35.14% |
| Viridian Therapeutics | -505.86% | -72.97% | -42.80% |
Volatility & Risk
ProQR Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
Insider and Institutional Ownership
32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for ProQR Therapeutics and Viridian Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProQR Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
| Viridian Therapeutics | 1 | 0 | 11 | 0 | 2.83 |
ProQR Therapeutics presently has a consensus price target of $7.60, indicating a potential upside of 429.62%. Viridian Therapeutics has a consensus price target of $38.92, indicating a potential upside of 55.29%. Given ProQR Therapeutics’ higher probable upside, research analysts plainly believe ProQR Therapeutics is more favorable than Viridian Therapeutics.
Earnings and Valuation
This table compares ProQR Therapeutics and Viridian Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProQR Therapeutics | $17.99 million | 8.40 | -$47.73 million | ($0.46) | -3.12 |
| Viridian Therapeutics | $71.13 million | 39.92 | -$342.60 million | ($3.37) | -7.44 |
ProQR Therapeutics has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
ProQR Therapeutics beats Viridian Therapeutics on 8 of the 14 factors compared between the two stocks.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
